Exonbio offers a comprehensive portfolio of SARS-CoV-2 antigens and antibodies.
We provide hundreds of recombinant rabbit monoclonal antibodies specific to SARS-CoV-2 Nucleocapsid and Spike protein. We also offer recombinant SARS-CoV-2 antigens: Human ACE2, Spike S1 subunit, RBD, RBD+SD1+SD2, Nucleoprotein, Numerous variants – Brazil, South Africa, Delta, Lambda, Omicron

Validation Data

Epitope Mapping

High-affinity monoclonal antibodies that fall in different epitope bins allow for antibody pairing for the development of ELISA kit. For detailed Nucleocapsid mAb pairing & clone information contact us.

Neutralization Assay

The two clones S185 and S422 display the best neutralization against the SARS-CoV-2 pseudo virus. The neutralization IC50 values are recorded in micro­ grams per millimeter.

SPR Screening

Crude supernatants containing rabbit monoclonal anti-NP antibodies were captured on protein A chip and nucleocapsid protein was injected at concentration of 300nM.

SARS-CoV-2 (2019-NCoV)

The World Health Organization (WHO) was informed of an outbreak of pneumonia from an unknown cause detected in Wuhan, China on the 31st of December 2019. After finding out the cause, today we know that the infectious agent was a virus from the coronavirus family, named SARS CoV-2 that causes a respiratory disease called Covid-19. Studying the details of how this virus replicates and causes the disease will allow scientists and physicians to more rapidly develop fast and accurate methods of detection as well as to deploy therapeutic and vaccine strategies. The genome of SARS CoV-2 encodes four main structural proteins: Nucleocapsid (N), Spike (S), Membrane (M), and Envelope (E). Two of these proteins appear to be important antigenic sites for the development of assays for detecting COVID-19, the Spike, and Nucleocapsid protein. Exonbio has developed a comprehensive range of recombinant proteins to help the scientific community accelerate COVID-19/SARS-CoV-2 research and development.